Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
← catalyst calendarNCT06697301 · readout ≤ 3,421 d
Sponsored by Eikon Therapeutics (industry) · EIKN — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
740estimated
Sites
107
Countries
Australia, Austria, Belgium +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-22 | actual | When the study began enrolling |
| Primary completion | Dec 2035 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Melanoma
Interventions
- Drug: EIK1001
- Drug: Pembrolizumab (KEYTRUDA® )
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured up to 5 years
Overall survival (OS)
measured up to 5 years
Objective Response (OR) (Dose Optimization Only)
measured up to 5 years
Adverse Events (AEs) (Dose Optimization Only)
measured up to 2.5 years
Permalink · EIKN's whole pipeline · Catalyst calendar · Every registered study · What changed